ONCR 788
Alternative Names: ONCR-788Latest Information Update: 28 Mar 2023
At a glance
- Originator Oncorus
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuroendocrine tumours; Prostate cancer; Small cell lung cancer
Most Recent Events
- 24 Mar 2023 ONCR 788 is available for licensing as of 24 Mar 2023
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in neuroendocrine tumors presented at the American Association for Cancer Research (AACR-2022)
- 27 May 2021 Oncorus plans to file IND application for ONCR 788 in Small cell lung cancer, Prostrate cancer and Neuroendocrine cancers in 2023